- Home
- ACRS vs ROOT Comparison
ACRS vs ROOT Comparison
Compare ACRS & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | ROOT |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 889.5M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACRS | ROOT |
|---|---|---|
| Price | $5.17 | $48.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.20 | ★ $92.40 |
| AVG Volume (30 Days) | ★ 2.4M | 161.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | 28.96 |
| EPS | N/A | ★ 3.58 |
| Revenue | $1,683,000.00 | ★ $1,517,100,000.00 |
| Revenue This Year | N/A | $11.73 |
| Revenue Next Year | $4.24 | $12.80 |
| P/E Ratio | ★ N/A | $13.35 |
| Revenue Growth | N/A | ★ 28.95 |
| 52 Week Low | $1.74 | $40.91 |
| 52 Week High | $6.60 | $94.04 |
Technical Indicators
Market Signals| Indicator | ACRS | ROOT |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 39.64 |
| Support Level | $4.99 | $48.26 |
| Resistance Level | $5.87 | $58.38 |
| Average True Range (ATR) | 0.36 | 2.11 |
| MACD | -0.05 | -0.53 |
| Stochastic Oscillator | 15.38 | 23.26 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.